Education
About Us
Working with TipRanks
Follow Us
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
ITCI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$64.09 - $131.71
Previous CloseN/A
Volume92.41K
Average Volume (3M)2.06M
Market Cap
$14.00B
Enterprise Value$6.75B
Total Cash (Recent Filing)$306.95M
Total Debt (Recent Filing)$16.98M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
May 13, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding106,327,950
10 Day Avg. Volume1,891,123
30 Day Avg. Volume2,063,812
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20.56
Price to Cash Flow (P/CF)-267.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.82
Enterprise Value/Ebitda-58.00
Forecast
1Y Price Target
$130.83Price Target Upside-0.66% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering13
---
Intra-Cellular Therapies News
PremiumCompany Announcements
Intra-Cellular Therapies Reports Strong 2024 Growth
PremiumPre-Earnings
Is ITCI a Buy, Before Earnings?
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCaplyta revenues of $199.2M were slightly above consensus, indicating better-than-expected financial performance.
Patent SettlementThe Caplyta patent settlement should provide an immediate boost to Caplyta's prospects and also to ITCI's prospects as a potential strategic target.
Regulatory ApprovalFDA accepted the sNDA for Caplyta in adjunctive MDD, highlighting progress in regulatory approval.
Bears Say
Pipeline ValuationOther ITCI pipeline products could be meaningful, but are earlier stage, making it difficult to ascribe value to them.
Stock TradingAnalyst is downgrading ITCI from Buy to HOLD as the stock is not trading on fundamentals.
---
Ownership Overview
1.37% Insiders
32.02% Mutual Funds
28.29% Other Institutional Investors
24.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ITCI FAQ
What was Intra-Cellular Therapies’s price range in the past 12 months?
Intra-Cellular Therapies lowest stock price was $64.09 and its highest was $131.71 in the past 12 months.
What is Intra-Cellular Therapies’s market cap?
Intra-Cellular Therapies’s market cap is $14.00B.
When is Intra-Cellular Therapies’s upcoming earnings report date?
Intra-Cellular Therapies’s upcoming earnings report date is May 13, 2025 which is in 49 days.
How were Intra-Cellular Therapies’s earnings last quarter?
Intra-Cellular Therapies released its earnings results on Feb 21, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.074 by -$0.086.
Is Intra-Cellular Therapies overvalued?
According to Wall Street analysts Intra-Cellular Therapies’s price is currently Overvalued.
Does Intra-Cellular Therapies pay dividends?
Intra-Cellular Therapies does not currently pay dividends.
What is Intra-Cellular Therapies’s EPS estimate?
Intra-Cellular Therapies’s EPS estimate is -0.09.
How many shares outstanding does Intra-Cellular Therapies have?
Intra-Cellular Therapies has 106,327,950 shares outstanding.
What happened to Intra-Cellular Therapies’s price movement after its last earnings report?
Intra-Cellular Therapies reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.074. Following the earnings report the stock price went up 0.047%.
Which hedge fund is a major shareholder of Intra-Cellular Therapies?
Currently, no hedge funds are holding shares in ITCI
---
Intra-Cellular Therapies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$130.83 (-0.66% Downside)
$130.83 (-0.66% Downside)
Blogger Sentiment
Bullish
ITCI Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 269.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.81%
12-Months-Change
Fundamentals
Return on Equity
-8.58%
Trailing 12-Months
Asset Growth
87.69%
Trailing 12-Months
Company Description
Intra-Cellular Therapies
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
---
ITCI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted robust growth in CAPLYTA sales and a strong financial position, supported by strategic investments in sales force expansion and promising pipeline developments. However, increased expenses and ongoing challenges in developing long-acting injectable formulations were noted as potential concerns.Read More>---
ITCI Stock 12 Month Forecast
Average Price Target
$130.83
▼(-0.66% Downside)
Technical Analysis
ACADIA Pharmaceuticals
―
Biogen
―
Neurocrine
―
Vertex Pharmaceuticals
―
SAGE Therapeutics
―
Best Analysts Covering ITCI
1 Year
1 Year Success Rate
29/30 ratings generated profit
1 Year Average Return
+47.83%
reiterated a buy rating 4 months ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 96.67% of your transactions generating a profit, with an average return of +47.83% per trade.
---